MBX Biosciences, Inc. MBX
Set alert
55.92 USD +0.05 +0.09%
As of Nov 2, 10:44 AM ET
55.63 Day range 57.42
20.21 52-week range 72.64
- YTD
- +77.30%
- 1 year
- +154.64%
- Open
- 55.97
- Prev close
- 55.87
- Mkt cap
- 2.69B
- Vol
- 62.61K
- Avg vol
- 512.38K
- EPS
- -2.37
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 55.63
- High
- 57.42
- Forward P/E
- -14.01
- Beta
- 0.10
- Short ratio
- 6.96
- Inst. own
- 116.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 58.03
- 200-d avg
- 45.52
- 1y target
- 95.70
6M chart
Events in this range
- May 7, 2026Earnings: -0.51; estimate -0.62; surprise 17.74%
- May 12, 2026Rating: Citizens · Market Outperform → Market Outperform
- May 12, 2026Rating: Barclays · Overweight → Overweight
- Jul 29, 2026Rating: Mizuho · Outperform → Outperform
- Aug 6, 2026Earnings: -0.78; estimate -0.63251; surprise -23.32%
- Aug 10, 2026Rating: Truist Securities · Buy → Buy
- Oct 2, 2026Rating: Guggenheim · Buy → Buy
- Oct 12, 2026Rating: Stifel · Buy → Buy
Signals (22)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| SMA: Bullish | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 6 months ago |
Key statistics
- Market cap
- 2.68B
- Enterprise value
- 2.21B
- Trailing P/E
- 0.00
- Forward P/E
- -14.01
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.52
- EPS (TTM)
- -2.37
- Beta
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -53.01M
- Total cash
- 418.58M
- Total debt
- 3.34M
- Return on equity
- -33.17%
- Shares outstanding
- 48.16M
- Short % of float
- 12.83%
- 50-day average
- 58.03
- 200-day average
- 45.52
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 95.70 +71.1% upside
Now 55.92
- Target (low)
- 80.00
- Target (mean)
- 95.70
- Target (high)
- 150.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.84465.
Financials — quick view
MBX Revenue — quarterly 0
MBX Net income — quarterly -37.09M
MBX EPS — quarterly -0.78
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.82675 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.63251 | -0.78 | -0.15 | -23.32% |
| May 7, 2026 | Mar 31, 2026 | -0.62 | -0.51 | +0.11 | +17.74% |
| Mar 12, 2026 | Dec 31, 2025 | -0.64 | -0.49 | +0.15 | +23.44% |
| Nov 6, 2025 | Sep 30, 2025 | -0.73 | -0.63 | +0.10 | +13.70% |
| Aug 7, 2025 | Jun 30, 2025 | -0.77 | -0.58 | +0.19 | +24.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Stifel | main | Buy | Buy |
| Oct 2, 2026 | Guggenheim | main | Buy | Buy |
| Aug 10, 2026 | Truist Securities | main | Buy | Buy |
| Jul 29, 2026 | Mizuho | main | Outperform | Outperform |
| May 12, 2026 | Barclays | main | Overweight | Overweight |
| May 12, 2026 | Citizens | main | Market Outperform | Market Outperform |
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mbxbio.com
News
- Microbix Attending & Presenting at IPVS 2026
- MBX Biosciences to Participate in Upcoming November Investor Conferences
- Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84
- Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150
- MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy?
- Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
- MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE
- MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
- MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Your note
Sign in to keep a note on MBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZOULAY SALOMON M.D. | Officer | Sale | Aug 3, 2026 | 14,399 |
| BARTRAM RICHARD B | Chief Financial Officer | Stock Award(Grant) | Feb 1, 2026 | 15,000 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 17, 2025 | 0 |
| HAWRYLUK P KENT | Chief Executive Officer | Sale | May 5, 2026 | 1,214,440 |
| HERON PATRICK J | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 25, 2025 | 0 |
| HOERTER STEVEN L | Chief Executive Officer | Stock Award(Grant) | Aug 2, 2026 | 102,938 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 13.81% | 6,652,013 | 370.58M | Jun 29, 2026 |
| FMR, LLC | 11.05% | 5,322,885 | 296.54M | Jun 29, 2026 |
| Wellington Management Group, LLP | 10.34% | 4,977,523 | 277.30M | Jun 29, 2026 |
| NEA Management Company, LLC | 7.51% | 3,614,486 | 201.36M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 7.12% | 3,428,736 | 191.01M | Jun 29, 2026 |
| Blackrock Inc. | 6.90% | 3,323,672 | 185.16M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.36% | 1,135,375 | 63.25M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.81% | 873,492 | 48.66M | Jun 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.70% | 817,600 | 45.55M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.67% | 805,557 | 44.88M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.41% | 680,000 | 37.88M | Aug 30, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.32% | 636,100 | 35.44M | Jul 30, 2026 |